Thomas Edward Hamilton bought $500K of Larimar Therapeutics (LRMR)
Executed Feb 27, disclosed Mar 2, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -14.2% (delay-adjusted); from the execution session (Feb 27), -16.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Thomas Edward Hamilton (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Larimar Therapeutics, Inc. (LRMR). Across 2 priced purchase filings, the average 21-session return was +2.2% from execution and +2.8% from disclosure (delay-adjusted; derived). The largest single filing was $500K of LRMR (100,000 sh × $5.00, as filed), executed Feb 27.
Healthcare · Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→50,000 sh × $3.34
Exec Jul 6
Filed Jul 8 · 4:05 PM ET